论文部分内容阅读
目的探讨前列地尔与西洛他唑、阿托伐他汀联合治疗糖尿病足临床疗效。方法分析本院自2011年1月~2014年l月本院收治的64例糖尿病足患者,按照随机数字表法分为对照组32例,给予前列地尔与西洛他唑联合应用,治疗组32例在对照组的基础上加用阿托伐他汀。比较两组临床疗效及症状改善情况。结果对照组与治疗组临床总有效率分别为31.25%(10/32),90.625%(29/32),两组比较(χ2=23.696,P=0.000<0.05)。对照组与治疗组比较,在疼痛[40.625%(13/32),43.75%(14/32)]、麻木[56.25%(18/32),50%(16/32)]改善方面比较(P>0.05),在肿胀[37.5%(12/32),9.375%(3/32)]、跛行[59.375%(19/32),25%(8/32)]改善方面比较(P<0.05)。结论前列地尔联合西洛他唑、阿托伐他汀治疗糖尿病足,可以有效提高临床有效率,改善临床症状。
Objective To investigate the clinical efficacy of alprostadil combined with cilostazol and atorvastatin in the treatment of diabetic foot. Methods Sixty-four patients with diabetic foot admitted to our hospital from January 2011 to January 2014 were randomly divided into control group (n = 32) and prostaglandin combined with cilostazol. The treatment group 32 cases in the control group based on the addition of atorvastatin. The clinical efficacy and symptom improvement were compared between the two groups. Results The total effective rates of the control group and the treatment group were 31.25% (10/32) and 90.625% (29/32), respectively (χ2 = 23.696, P = 0.000 <0.05). Compared with the treatment group, there was no significant difference between the control group (40.625% (13/32), 43.75% (14/32), numbness (56.25%, 18/32) and 50% (16/32) (P <0.05) in terms of swelling (37.5% (12/32), 9.375% (3/32)], claudication [59.375% (19/32), 25% (8/32) . Conclusions Alprostadil combined with cilostazol and atorvastatin in treating diabetic foot can effectively improve clinical efficiency and improve clinical symptoms.